Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 06 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Brivaracetam Tablets, along with shared exclusivity rights. The approval allows Zydus to market multiple strengths of Brivaracetam Tablets, which are used to treat partial-onset seizures in patients aged four and older. This filing highlights Zydus's position as one of the first applicants to submit a complete application for this drug, qualifying for a period of exclusivity. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had significant annual sales in the US market according to recent data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases